3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD

Keywords

• *Asthma/drug therapy
• Cross-Sectional Studies
• Humans
• *Pulmonary Disease, Chronic Obstructive/drug therapy
• payment or honoraria from AstraZeneca, GlaxoSmithKline, Novartis, TEVA, Sanofi,
• Chiesi and ALK in the 36 months prior to manuscript submission. Conflict of
• interest: A.H. Maitland-van der Zee declares unrestricted research grants from
• Vertex and Boehringer Ingelheim, and is the principal investigator of a Precision
• Medicine for more Oxygen (P4O2) public private partnership sponsored by Health
• Holland involving cash or in kind contributions from Boehringer Ingelheim,
• Breathomix, Fluidda, Ortec Logiqcare, Philips, Quantib-U, Smartfish, SODAQ, Thirona,
• TopMD and Novartis
• consulting fees paid to their institution by AstraZeneca and
• Boehringer Ingelheim
• and payment or honoraria paid to their institution by
• GlaxoSmithKline, all in the 36 months prior to manuscript submission. They declare
• that they are an unpaid member of the Data Safety Monitoring Board of the SOS BPD
• Study
• that they are unpaid president of the Federation of Innovative Drug Research
• in the Netherlands (FIGON)
• and that they are president of the European Association
• of Systems Medicine. Conflict of interest: G. Brusselle declares payment or
• honoraria from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis,
• Sanofi and Teva in the 36 months prior to manuscript submission. Conflict of
• interest: G.W. Canonica declares no competing interests. Conflict of interest: A.
• Agusti declares no competing interests. Conflict of interest: R. Faner declares
• research grant payments from GlaxoSmithKline, Menarini, AstraZeneca, ISC-III and the
• Spanish National Health Service
• consulting fees from GlaxoSmithKline
• and payments
• or honoraria from Chiesi, all in the 36 months prior to manuscript submission.
• Conflict of interest: C.F. Vogelmeier declares grant payments to their institution
• from the German Ministry of Education and Science (BMBF), AstraZeneca, Boehringer
• Ingelheim, GlaxoSmithKline, Grifols and Novartis
• consulting fees from AstraZeneca,
• Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Menarini, Novartis and
• Nuvaira
• payments or honoraria from Aerogen, AstraZeneca, Boehringer Ingelheim, CSL
• Behring, Chiesi, GlaxoSmithKline, Menarini and Novartis, all in the 36 months prior
• to manuscript submission. Conflict of interest: M. Nawijn declares unrestricted
• research grant payments to their institution from Chan Zuckerberg Initiative and
• GlaxoSmithKline in the 36 months prior to manuscript submission
• and that they are
• coordinator of the Human Cell Atlas Lung Biological Network. Conflict of interest:
• M. van den Berge declares research grant payments to their institution from
• GlaxoSmithKline, AstraZeneca, Novartis, Genentech and Roche in the 36 months prior
• to manuscript submission. Conflict of interest: F. Rusconi declares no competing
• interests. Conflict of interest: C. Pilette declares no competing interests.
• Conflict of interest: V. Ramiconi declares unrestricted educational grant payments
• to her organisation from Novartis, Pfizer, AstraZeneca, Chiesi, GlaxoSmithKline,
• AbbVie, LeoPharma, Boehringer Ingelheim, Sanofi, Regeneron, OM Pharma, Merck Sharp &
• Dohme, Roche and DBV Technologies, in the 36 months prior to manuscript submission.
• Conflict of interest: C. Coleman is an employee of the European Lung Foundation.
• Conflict of interest: R. Chaudhuri declares funding from 3TR European Union
• Innovative Medicines Initiative 2 to their institution for the present manuscript.
• They also declare grant funding from AstraZeneca within a Medical Research Council
• project
• lecture fees from GlaxoSmithKline, AstraZeneca, Teva, Chiesi, Sanofi and
• Novartis
• support for attending conferences from Chiesi, Napp, Sanofi, Boehringer
• Ingelheim, GlaxoSmithKline and AstraZeneca
• and participation on advisory boards for
• GlaxoSmithKline, AstraZeneca, Teva, Chiesi and Novartis, all in the 36 months prior
• to manuscript submission. Conflict of interest: K.F. Chung declares grant payments
• to their institution from the Medical Research Council (precision medicine for
• severe asthma), the Engineering and Physical Sciences Research Council (air
• pollution and asthma) and GlaxoSmithKline (eosinophils)
• consulting fees from the
• scientific committee of the Clean Breathing Institute (funded by the GlaxoSmithKline
• consumer division)
• speaking fees for engagements from Novartis and AstraZeneca
• an
• educational grant paid to their institution for the 11th London International Cough
• Symposium from AstraZeneca, Merck, Shionogi, Nocion, Bellus and Bayer
• participation
• on a data safety management board for Nocion (antitussive)
• and participation on
• advisory boards for Nocion, Shionogi and Merck (antitussives) and GlaxoSmithKline,
• Roche and Novartis (asthma and COPD), all in the 36 months prior to manuscript
• submission. Conflict of interest: J. Wedzicha declares grant payments to their
• institution from GlaxoSmithKline, AstraZeneca, Novartis, Genentech, Boehringer
• Ingelheim and Chiesi
• paid participation on a Data Safety Monitoring Board for
• Virtus
• and editorship of the American Journal of Respiratory and Critical Care
• Medicine, for which an honorarium is paid jointly to them and their institution.
• Conflict of interest: S. Saglani declares no competing interests. Conflict of
• interest: M.P. Van der Schee declares consulting fees from Owlstone Medical in the
• 36 months prior to manuscript submission
• and that they hold stock or stock options
• in Owlstone Medical and Sanome. Conflict of interest: L. Heaney declares grant
• payments to their institution from Novartis UK, GlaxoSmithKline, Amgen,
• Genentech/Hoffmann la Roche, AstraZeneca, Medimmune, Aerocrine and Vitalograph
• payments or honoraria from Novartis, Genentech/Hoffmann la Roche, Sanofi, Evelo
• Biosciences, GlaxoSmithKline, AstraZeneca, Teva, Theravance and Circassia
• support
• for attending meetings from AstraZeneca, Boehringer Ingelheim, Chiesi,
• GlaxoSmithKline and Napp
• and participation on advisory boards for Novartis,
• Genentech/Hoffmann la Roche, Sanofi, Evelo Biosciences, GlaxoSmithKline,
• AstraZeneca, Teva, Theravance and Circassia, all in the 36 months prior to
• manuscript submission. Conflict of interest: A. Bourdin declares unrestricted grant
• payments from AstraZeneca and Boehringer Ingelheim
• advisory board fees from
• AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi, Novartis, Chiesi, Amgen
• lecture
• payments from AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi, Novartis, Chiesi and
• Amgen
• and support for attending meetings from AstraZeneca, GlaxoSmithKline,
• Regeneron, Sanofi and Novartis, all in the 36 months prior to manuscript submission.
• Conflict of interest: G. Roberts declares funding from 3TR European Union Innovative
• Medicines Initiative 2 to their institution for the present manuscript. Conflict of
• interest: R. Djukanovic declares consulting fees from Synairgen plc in the 36 months
• prior to manuscript submission
• that they are chair of the European Respiratory
• Society Clinical Research Collaboration on severe asthma (SHARP)
• and that they hold
• shares in Synairgen plc. Conflict of interest: P. Kuna declares lecture fees from
• Adamed, AstraZeneca, Boehringer Ingelheim, Berlin Chimie, Menarini, Chiesi, HAL
• Allergy, Lekam, Mylan, Novartis, Polpharma and Teva in the 36 months prior to
• manuscript submission. Conflict of interest: M. Kupczyk declares funding from 3TR
• European Union Innovative Medicines Initiative 2 for the present manuscript. They
• also declare payment or honoraria from AstraZeneca, Chiesi, GlaxoSmithKline,
• Novartis, Lekam, Alvogen, Emma, Nexter and Berlin Chemie in the 36 months prior to
• manuscript submission. Conflict of interest: J. Axmann declares no competing
• interests. Conflict of interest: H. Staudinger declares that they are an employee of
• Sanofi Genzyme
• and that they hold stock or stock options in Sanofi and Merck.
• Conflict of interest: G.W. Clarke declares that they are an employee of AstraZeneca
• and that they hold stock or stock options in AstraZeneca. Conflict of interest: S.E.
• Dahlen declares consulting fees from AstraZeneca, Caiman Chemicals, GlaxoSmithKline,
• Merck, Novartis, Regeneron, Sanofi and Teva, outside the present manuscript.
• Conflict of interest: C. Brightling declares support from 3TR European Union
• Innovative Medicines Initiative 2 for the present manuscript. They also declare
• grant payments to their institution from GlaxoSmithKline, AstraZeneca, Novartis,
• Chiesi, Sanofi, Genentech, Merck, Mologic, 4DPharma and Gossamer
• consulting fees
• paid to their institution from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim,
• Novartis, Chiesi, Sanofi, Genentech, Merck, Mologic, 4DPharma, Gossamer, TEVA,
• Regeneron, Roche and CSL Behring, all in the 36 months prior to manuscript
• submission.